Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCreo Medical Regulatory News (CREO)

Share Price Information for Creo Medical (CREO)

Share Price is delayed by 15 minutes
Get Live Data
13.50    0.00 (0.00%)
Bid:
13.25
Ask:
13.75
Spread: 0.50 (3.774%)
Market Cap: £65.58m
CREO Live PriceLast checked at - London Stock Exchange

Intraday Creo Medical Share Chart

Call Option Agreement

21 Nov 2008 09:24

RNS Number : 6520I
China Real Estate Opportunities Ltd
21 November 2008
 

China Real Estate Opportunities Limited

 

CREO ANNOUNCES CALL OPTION IN RREEF CHINA COMMERICIAL TRUST

 

21 November 2008, Hong Kong - China Real Estate Opportunities Limited ("CREO" or the "Company"), an AIM listed property company with an established investment and development portfolio in China today announced that it had entered into a call option agreement to acquire a 25.65% stake or 119,043,500 units in RREEF China Commercial Trust ("RREEF CCT"), a Hong Kong-listed Real Estate Investment Trust ("REIT"), to be exercised on 12 January 2009 at a cost of HKD 387 million (£33.6 million). 

RREEF CCT listed on the Hong Kong Stock Exchange on 22 June 2007 and currently owns an international grade A office and retail complex in the Chaoyang District of Beijing. The property, Beijing Gateway Plaza, is a strongly performing commercial real estate asset of approximately 130,000 square metres, with occupancy of over 95%, and is entirely consistent with CREO's long-term investment and operating philosophy.

RREEF CCT is managed by RREEF China Reit Management Limited, which is owned by RREEF Alternative Investments through Deutsche Bank Asia Pacific.

As at June 2008, RREEF CCT had a net asset value (NAV) of HKD6.04 per share, whilst the individual asset had a gross property value of HKD8.56 per share (HKD3.99 billion, £347.0 million). An interim dividend of HKD18.63 cents per share was paid in June 2008. Based on the share price of HKD1.880 on 20 November 2008, RREEF CCT had a market capitalisation of HKD873 million (£75.9 million). 

CREO has secured the call option at HKD3.25 per share representing a 46% discount to NAV and 62% discount to gross property valueBased on the interim dividend outlined in the June 2008 interim accounts the exercise price of the call option of HKD3.25 equates to a dividend yield of 11.5% per annum.

Mr. Ray Horney, Chairman of China Real Estate Opportunities Limited said, "This transaction reinforces CREO's ongoing commitment to its core business and exhibits its capacity to identify strategic investments that maintain its position as one of the leading foreign investors in China's commercial real estate market and that are accretive to its existing investments".

-- Ends --

About CREO

CREO was listed on the AIM market in London on 11th July 2007 under ticker symbol CREO, having successfully raised £259 million. Harnessing the intimate local market knowledge and key relationships that Treasury Holdings has been able to develop through its presence in China since 2002, CREO's principal objective is to maximise capital growth from a portfolio of properties in China. The projects will all incorporate high quality design, specifications, and finishes synonymous with Treasury Holdings.

CREO, with an exclusive focus on the China real estate market currently owns seven high-quality, strategically located properties in ShanghaiBeijing, and Qingdao. The company's main focus is in the commercial real estate sector, with income-producing properties currently representing 75% of the total portfolio.

www.china-reo.com

www.treasuryholdings.com

For further information, please contact:

CREO

Ray Horney, Chairman

Tel: + 44 (0)1273 775225

Sarah Moriarty, Investor Relations 

Tel: +353 1 6189455

Treasury Holdings China 

Richard David, Managing Director

Tel: (+86) 21 6282 5000 

Davy

Des Carville

Tel: +353 1 679 6363

Media Enquiries:

Bankside Consultants

Simon Rothschild, Oliver Winters

Tel: + 44 (0)207 367 8888

Murray Consultants

Ed Micheau

Tel: + 3531 498 0300

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGREAPFFADAPFEE
Date   Source Headline
23rd Jun 20267:00 amRNSAppointment of Nominated Adviser /Corporate Broker
4th Jun 20267:00 amRNSPosting of 2025 Annual Report and Notice of AGM
28th May 20262:35 pmRNSHolding(s) in Company
22nd May 202610:11 amRNSResult of Placing
22nd May 20267:02 amRNSProposed Placing to raise approximately £5.5m
22nd May 20267:01 amRNSFY25 Final Results
22nd May 20267:00 amRNSProposed Sale of 49% Interest in Creo Medical SL
7th May 20267:00 amRNS-RMicroBlate™ Fine commercial update
5th May 20267:00 amRNS-RSpydrBlade™ Flex used in novel BEAM procedures
30th Apr 20267:00 amRNS-RKOL presentations on Creo Core Products at DDW
29th Apr 20267:00 amRNS-RUK private hospital use Speedboat for cancer case
22nd Apr 20267:00 amRNSPositive Q1 trading update
16th Apr 20267:00 amRNSDisposal and outsourcing of manufacturing
24th Feb 20267:00 amRNSAppointment of Joint Corporate Broker
20th Jan 20267:00 amRNSFY25 Trading Update
14th Jan 20267:00 amRNSAward of Shares under Share Incentive Plan
27th Oct 20257:00 amRNSNotice of Capital Markets Day
7th Oct 202511:37 amRNSCapital Markets Day update
22nd Sep 20257:00 amRNSUnaudited results for the six months ended 30 June
12th Sep 20253:14 pmRNSHolding(s) in Company
11th Sep 20257:00 amRNSNotice of Results
12th Aug 20254:56 pmRNSDirector/PDMR Share Dealing
4th Aug 20257:00 amRNS-RSpeedboat® patient testimonial
24th Jul 20257:00 amRNSAward of Shares under SIP and Director Dealings
21st Jul 20257:00 amRNSH1’25 Trading Update
10th Jul 20257:00 amRNS-RMicroBlate™ Flex begins lung tumour clinical study
9th Jul 20259:41 amRNSPDMR Options Revision
30th Jun 20257:00 amRNSChange of Nominated Adviser
26th Jun 202511:08 amRNSResult of AGM
26th Jun 20257:00 amRNSAGM Statement and Directorate Changes
11th Jun 20257:00 amRNS-RU.S. FDA clearance for SpydrBlade™ Flex
2nd Jun 20257:00 amRNSDirector/PDMR Shareholding
30th May 20257:00 amRNSPosting of AR&R and Notice of AGM
28th May 20257:00 amRNSUS Reimbursement milestone for Speedboat procedure
27th May 202512:48 pmRNSHolding(s) in Company
23rd May 20254:25 pmRNSHolding(s) in Company
22nd May 20257:00 amRNSDirectorate changes
19th May 20257:00 amRNSFinal Results
6th May 20257:00 amRNSNotice of investor presentations
15th Apr 20252:00 pmRNSNotice of Results
1st Apr 20259:34 amRNSHolding(s) in Company
31st Mar 202512:17 pmRNSHolding(s) in Company
26th Mar 20257:00 amRNSGrant of Options
20th Mar 20257:00 amRNS-RUK & EU Commercial launch of SpydrBlade™ Flex
6th Mar 20257:00 amRNSAppointment of Nominated Adviser and sole Broker
17th Feb 20257:00 amRNSFY24 Trading Update
12th Feb 202511:00 amRNSCompletion of sale of 51% interest in subsidiary
6th Feb 20259:00 amRNS-RFirst Welsh adopter of Speedboat® technology
3rd Feb 20253:00 pmRNSTotal Voting Rights
21st Jan 20257:00 amRNSAward of Shares under Share Incentive Plan

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.